Gastrointestinal features of Parkinson's disease

Current Neurology and Neuroscience Reports

Volumn 11, Issue 4, 2011, Pages 379-384

  Cloud, Leslie J ^b   Greene, James G ^a  

^a EMORY UNIVERSITY   (United States)

^b NONE

Author keywords

Apomorphine; Aspiration; Atropine; Bloating; Botulinum toxin; Constipation; Defecatory dysfunction; Domperidone; Dysphagia; Early satiety; Gastrointestinal; Gastroparesis; Glycopyrrolate; Ipratropium bromide; Laxatives; Nausea; Nonmotor symptoms; Parkinson's disease; Polyethylene glycol; Psyllium; Reflux; Sialorrhea; Vomiting; Weight loss

Indexed keywords

APOMORPHINE; ATROPINE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; ISPAGULA; MACROGOL; PLACEBO;

ANHIDROSIS; ARTICLE; BLURRED VISION; BRAIN DEPTH STIMULATION; CONFUSION; CONSTIPATION; DEFECATION DISORDER; DELIRIUM; DROWSINESS; DRY NOSE; DYSGEUSIA; DYSPHAGIA; ELECTROLYTE DISTURBANCE; EPISTAXIS; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART DISEASE; HEART PALPITATION; HUMAN; HYPERSALIVATION; HYPOTENSION; NAUSEA; PARKINSON DISEASE; PROLACTIN BLOOD LEVEL; SIDE EFFECT; STOMACH PARESIS; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; DEFECATION; GASTROINTESTINAL TRACT; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CONSTIPATION; DEFECATION; DEGLUTITION DISORDERS; GASTROINTESTINAL TRACT; HUMANS; NAUSEA; PARKINSON DISEASE; SIALORRHEA; WEIGHT LOSS;

EID: 80054821748     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-011-0204-0     Document Type: Article

References (71)

1. Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2003;2:107-16. (Pubitemid 37443331)
2. Pfeiffer RF: Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2011;17:10-15. This is an excellent review of the clinical aspects of GI dysfunction in PD.
3. Jost WH. Gastrointestinal dysfunction in Parkinson's Disease. J Neurol Sci. 2010;289:69-73.
4. Sakakibara R, Uchiyama T, Yamanishi T, et al. Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm. 2008;115:443-60.
5. Lebouvier T, Chaumette T, Paillusson S, et al.: The second brain and Parkinson's disease. Eur J Neurosci. 2009;30:735-41. This is an excellent review of available studies on the enteric nervous system in PD patients and in animal models of the disease.
6. Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology. Neurology. 1992;42:726-32.
7. Li H, Zhang M, Chen L, et al. Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson's disease. Mov Disord. 2010;25(16):2740-6.
8. Visser M, Van Rooden SM, Verbaan D, et al. A comprehensive model of health-related quality of life in Parkinson's disease. J Neurol. 2008;255:1580-7.
9. Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnairebased assessment of pelvic organ dysfunction in Parkinson's Disease. Auton Neurosci. 2001;92:76-85. (Pubitemid 32757250)
10. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord. 2009;24:1641-9.
11. Robbins JA, Logemann JA, Kirshner HS. Swallowing and speech production in Parkinson's disease. Ann Neurol. 1986;19:283-7. (Pubitemid 16111078)
12. Rosenthal MJ, Marshall CE. Sigmoid volvulus in association with parkinsonism. Report of four cases. J Am Geriatr Soc. 1987;35:683-4. (Pubitemid 17089058)
13. Caplan LH, Jacobson HG, Rubinstein BM, et al. Megacolon and Volvulus in Parkinson's Disease. Radiology. 1965;85:73-9.
14. Kupsky WJ, Grimes MM, Sweeting J, et al. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology. 1987;37:1253-5. (Pubitemid 17130769)
15. Bushmann M, Dobmeyer SM, Leeker L, et al. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology. 1989;39:1309-14. (Pubitemid 19246802)
16. Bird MR, Woodward MC, Gibson EM, et al. Asymptomatic swallowing disorders in elderly patients with Parkinson's disease: a description of findings on clinical examination and videofluoroscopy in sixteen patients. Age Ageing. 1994;23:251-4. (Pubitemid 24158297)
17. Guneysel O, Onultan O, Onur O. Parkinson's disease and the frequent reasons for emergency admission. Neuropsychiatr Dis Treat. 2008;4:711-4.
18. Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology. 1988;38:419-21. (Pubitemid 18083681)
19. Djaldetti R, Baron J, Ziv I, et al. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology. 1996;46:1051-4. (Pubitemid 26134650)
20. Djaldetti R, Achiron A, Ziv I, et al. First emergence of "delayed-on" and "dose failure" phenomena in a patient with Parkinson's disease following vagotomy. Mov Disord. 1994;9:582-3. (Pubitemid 24275076)
21. Abbott RA, Cox M, Markus H, et al. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr. 1992;46:879-84. (Pubitemid 23023500)
22. Beyer PL, Palarino MY, Michalek D, et al. Weight change and body composition in patients with Parkinson's disease. J Am Diet Assoc. 1995;95:979-83.
23. Durrieu G, Llau ME, Rascol O, et al. Parkinson's disease and weight loss: a study with anthropometric and nutritional assessment. Clin Auton Res. 1992;2:153-7.
24. Jaafar AF, Gray WK, Porter B, et al. A cross-sectional study of the nutritional status of community-dwelling people with idiopathic Parkinson's disease. BMC Neurol. 2010;10:124.
25. Eadie M, Tyrer JH. Alimentary disorders in parkinsonism. Aust Ann Med. 1965;14:13-22.
26. Edwards LL, Pfeiffer RF, Quigley EM, et al. Gastrointestinal symptoms in Parkinson's disease. Mov Disord. 1991;6:151-6.
27. Tumilasci OR, Cersosimo MG, Belforte JE, et al. Quantitative study of salivary secretion in Parkinson's disease. Mov Disord. 2006;21:660-7. (Pubitemid 43792747)
28. Nobrega AC, Rodrigues B, Torres AC, et al. Is drooling secondary to a swallowing disorder in patients with Parkinson's disease? Parkinsonism Relat Disord. 2008;14:243-5. (Pubitemid 351458424)
29. Arbouw ME, Movig KL, Koopmann M, et al.: Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010;74:1203-7. This provides level I evidence for glycopyrrolate to treat sialorrhea in PD.
30. Thomsen TR, Galpern WR, Asante A, et al.: Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord. 2007;22:2268-73. This provides level I evidence for ipratropium to treat sialorrhea in PD.
31. Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002;17:1318-20. (Pubitemid 36041348)
32. Ondo W, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology. 2004;62:37-40. (Pubitemid 38082867)
33. Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2006;21:704-7. (Pubitemid 43792756)
34. Edwards L, Quigley EM, Hofman R, Pfeiffer RF. Gastrointestinal symptoms in Parkinson's disease: and 18-month follow-up study. Mov Disord. 1993;8:83-6. (Pubitemid 23039236)
35. Ali GN, Wallace KL, Schwartz R, et al. Mechanisms of oralpharyngeal dysphagia in patients with Parkinson's disease. Gastroenterology. 1996;110:383-92. (Pubitemid 26043870)
36. Castell JA, Johnston BT, Colcher A, et al. Manometric abnormalities of the oesophagus in patients with Parkinson's disease. Neurogastroenterol Motil. 2001;13:361-4. (Pubitemid 32953672)
37. Stroudley J, Walsh M. Radiological assessment of dysphagia in Parkinson's disease. Br J Radiol. 1991;64:890-3.
38. Fuh JL, Lee RC, Wang SJ, et al. Swallowing difficulty in Parkinson's disease. Clin Neurol Neurosurg. 1997;99:106-12.
39. Leopold NA, Kagel MC. Laryngeal deglutition movement in Parkinson's disease. Neurology. 1997;48:373-6.
40. Potulska A, Friedman A, Krolicki L, et al. Swallowing disorders in Parkinson's disease. Parkinsonism Relat Disord. 2003;9:349-53. (Pubitemid 36809036)
41. Bassotti G, Germani U, Pagliaricci S, et al. Esophageal manometric abnormalities in Parkinson's disease. Dysphagia. 1998;13:28-31. (Pubitemid 28029971)
42. Tison F, Wiart L, Guatterie M, et al. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease. Mov Disord. 1996;11:729-32. (Pubitemid 26381947)
43. Nagaya M, Kachi T, Yamada T. Effect of swallowing training on swallowing disorders in Parkinson's disease. Scand J Rehabil Med. 2000;32:11-5.
44. Goetze O, Nikodem AB, Wiezcorek J, et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil. 2006;18:369-75.
45. Hardoff R, Sula M, Tamir A, et al. Gastric emptying time and gastric motility in patients with Parkinson's Disease. Mov Disord. 2001;16:1041-47. (Pubitemid 36041216)
46. Soykan I, Sarosiek I, Shifflett J, et al. Effect of chronic oral domperidine therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Mov Disord. 1997;12:952-7. (Pubitemid 27496773)
47. Djaldetti R, Koren M, Ziv I, et al. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord. 1995;10:81-4.
48. Asai H, Udaka F, Hirano M, et al. Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease. Parkinsonism Relat Disord. 2005;11:499-502. (Pubitemid 41627841)
49. Jost WH, Schimrigk K. Constipation in Parkinson's disease. Klin Wochenschr. 1991;69:906-9.
50. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time and rectoanal videomanometry in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74:268-72. (Pubitemid 36160697)
51. Edwards LL, Quigley EM, Harned RK, et al. Characterization of swallowing and defecation in Parkinson's disease. Am J Gastroenterol. 1994;89:15-25. (Pubitemid 24020046)
52. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001;57:456-62. (Pubitemid 32757593)
53. Abbott RD, Ross GW, Petrovitch H, et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord. 2007;22:1581-6. (Pubitemid 47477919)
54. Petrovitch H, Abbott RD, Ross GW, et al. Bowel movement frequency in late-life and substantia nigra neuron density at death. Mov Disord. 2009;24:371-6.
55. Ashraf W, Pfeiffer R, Park F, et al. Constipation in Parkinson's Disease: objective assessment and response to psyllium. Mov Disord. 1997;12:946-51. (Pubitemid 27496772)
56. Eichhorn T, Oertel W. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord. 2001;16:1176-7. (Pubitemid 36041238)
57. Zangaglia R, Martignoni E, Glorioso M, et al.: Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord. 2007;22:1239-44. This provides level I evidence for polyethylene glycol to treat constipation in PD. (Pubitemid 47325029)
58. Jost W, Schimrigk K. Cisapride treatment of constipation in Parkinson's disease. Mov Disord. 1993;8:339-43. (Pubitemid 23212545)
59. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5- HT4 agonist and partial 5-HT3 antagonist, ameloriates constipation in parkinsonian patients. Mov Disord. 2005;20:680-6. (Pubitemid 41051779)
60. Morgan J, Sethi K. Tegaserod in constipation associated with Parkinson Disease. Clin Neuropharmacol. 2007;30:52-4. (Pubitemid 46204319)
61. Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol. 1989;46:1061-4. (Pubitemid 19246293)
62. Mathers SE, Kempster PA, Swash M, et al. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatry. 1988;51:1503-7. (Pubitemid 19026520)
63. Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol. 1993;33:490-3. (Pubitemid 23143032)
64. Albanese A, Maria G, Bentivoglio AR, et al. Severe constipation in Parkinson's disease relieved by botulinum toxin. Mov Disord. 1997;12:764-6. (Pubitemid 27406276)
65. Cadeddu F, Bentivoglio A, Brandara F, et al. Outlet type constipation in Parkinson's disease:results of botulinum toxin treatment. Aliment Pharmacol Ther. 2005;22:997-1003. (Pubitemid 41634882)
66. Wiley J, Owyang C. Dopaminergic modulation of rectosigmoid motility: action of domperidone. J Pharmacol Exp Ther. 1987;242:548-51. (Pubitemid 17143487)
67. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord. 2006;21:524-9.
68. Ciucci MR. Subthalamic nucleus deep brain stimulation improves deglutition in Parkinson's Disease. Mov Disord. 2008;23:676-83.
69. Zibetti M, Torre E, Cinquepalmi A, et al. Motor and nonmotor symptom follow-up in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. Eur Neurol. 2007;58:218-23. (Pubitemid 350175889)
70. Tuite PJ, Maxwell RE, Ikramuddin S, et al. Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgery. Parkinsonism Relat Disord. 2005;11:247-52. (Pubitemid 40692837)
71. Walker HC, Lyerly M, Cutter G, et al. Weight changes associated with unilateral STN DBS and advanced PD. Parkinsonism Relat Disord. 2009;15:709-11.